James H. Doroshow, M.D.
Laboratory of Molecular Pharmacology
Director, Division of Cancer Treatment and Diagnosis
National Cancer Institute
9000 Rockville Pike
Building 31, Room 3A44
Bethesda, MD 20892
Dr. Doroshow has been Director of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), since 2004. From 1983 to 2004, Dr. Doroshow was the associate director for clinical research at the City of Hope (COH) Comprehensive Cancer Center in Duarte, Calif; the chairman of the COH Department of Medical Oncology and Therapeutics Research; and the leader of the COH Cancer Center's Clinical and Experimental Therapeutics Program. From the time he received his first research grant in 1980, Dr. Doroshow was continuously funded by NCI and NIH until moving to NCI in 2004. He is the author of over 300 full-length publications in the areas of the molecular and clinical pharmacology of the anthracycline antibiotics, the role of oxidant stress in signal transduction, and novel therapeutic approaches to breast, gastrointestinal, lung, and gynecologic cancer.
Dr. Doroshow's Clinical Trial(s):
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with solid tumors. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.